In eight patients, the right ventricular effective refrac• tory period, rate-«iependent changes in intraventricular conduction (as reflected by QRS duration during ven• tricular paced cycle lengths of 600 to 250 ms) and results of programmed ventricular stimulation were determined in the control state, 5 minutes after the intravenous in• fusion of 10 mg/kg body weight of amiodarone and after 2 months of treatment with oral amiodarone. The right ventricular effective refractory period was 230 ± 30 ms (mean ± SD) in the control study, 248 ± 27 ms after intravenous amiodarone (p < 0.001) and 296 ± 26 ms after oral amiodarone (p < 0.001). In the control state, QRS duration was constant at all paced cycle lengths. Intravenous amiodarone resulted in a rate-dependent prolongation ofQRS duration. This rate-dependent pro• longation was markedly accentuated by oral amiodarone in six patients who had an elevated serum level of reverse triiodothyronine (T 3) after 2 months of oral treatment, but it was not more pronounced than the effects of in• travenous amiodarone in two patients with a normal reverse T 3 serum level after oral therapy. Both intra-
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The clinical response and results of programmed ventricular stimulation in patients with malignant ventricular arrhyth• mias treated chronically with oral amiodarone have been extensively studied (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) . Much less information has been gathered on the acute effects of intravenous administration of amiodarone. Intravenous amiodarone was found to sup• press ventricular arrhythmias in some studies (11-16), but not in others (17, 18) . It was reported not to prolong ven• tricular refractoriness significantly in studies (15, 18, 19) in which only a dose of 5 mg/kg body weight was used. One venous and oral amiodarone either suppressed or mod• ified the induction of ventricular iachycardia by pro• grammed stimulation in some patients, but in a discordant fashion. The relative effects of intravenous and oral amiodarone on ventricular refractoriness and conduc• tion and on ventricular tachycardia induction did not correlate with serum amiodarone levels.
Chronic amiodarone therapy results in a marked pro• longation in ventricular refractoriness compared with the relatively small but significant increase that occurs after intravenous amiodarone. Accentuation by oral amiodarone of the rate-dependent slowing of intraven• tricular conduction caused by intravenous amiodarone may be related to a direct electrophysiologic effect of amiodarone that is potentiated by an amiodarone-in• duced abnormality in thyroid hormone metabolism. The different effects of intravenous and oral amiodarone on ventricular tachycardia induction may be explained by different relative effects on refractoriness and conduction. (J Am Coil CardioI1986; 7:148-57) prior study (18) compared, in the same patients, the acute and chronic effects of amiodarone on ventricular refracto• riness and ventricular tachycardia induction, but the effects on tachycardia were evaluated in only three patients. More• over, although the rate-dependent effects of amiodarone on intraventricular conduction have been studied in relation to acute intravenous administration (20), they have not been studied in relation to long-term oral administration.
Some investigators (21, 22) have found that the thera• peutic effects of amiodarone occur within a particular range of amiodarone serum levels, while others (23) have reported that an elevation in the serum level of reverse triiodothy• ronine (T 3 ) correlates with amiodarone's therapeutic effect. The latter observation led to the suggestion that the effects of amiodarone may be at least in part related to the distur• bance in thyroid hormone metabolism induced by amio-darone (24) . However, no prior study has examined the relation between serum levels of reverse T 3 
and amioda• rone's effects on ventricular refractoriness and conduction in humans.
The aim of the present study was to compare, in the same patients, the effects of high dose intravenous (10 mg/kg) and long-term oral amiodarone therapy on ventricular re• fractoriness, intraventricular conduction and ventricular tachycardia induction. In addition, the relation among the electrophysiologic effects and serum concentrations of amiodarone, its principal metabolite (desethylamiodarone) and reverse T 3 were examined.
Methods
Patient characteristics. The subjects of this study con• sisted of eight patients: five with recurrent, sustained ven• tricular tachycardia, two with out-of-hospital cardiac arrest and one with recurrent, nonsustained ventricular tachycar• dia. There were seven men and one woman, with a mean age of 61 ± 7 years (± 1 SD). All eight patients had coronary artery disease and a remote history of myocardial infarction. The mean left ventricular ejection fraction de• termined by contrast or radionuclide ventriculography was 0.38 ± 0.13% (range 0.20 to 0.59). Before participation in this study, each patient underwent programmed ventric• ular stimulation and had inducible sustained ventricular tachycardia in the drug-free state. Before being treated with amiodarone, these patients underwent a mean of 2.8 ± I drug trials that were ineffective in controlling ventricular tachycardia either clinically or during electropharmacologic testing.
Electrophysiologic testing protocol. After informed consent was obtained under a protocol approved by the Committee on Human Research at the University of Mich• igan, the patients were brought to the electrophysiology laboratory in the fasting, unsedated state after all antiar• rhythmic drugs had been discontinued for at least four half• lives. Two quadripolar electrode catheters were inserted percutaneously into a femoral vein and positioned in the right ventricular apex and in the outflow tract or at the septum. Arterial blood pressure was monitored continuously with a 5F cannula inserted percutaneously into a femoral artery. Electrocardiographic leads V J, I and III, the right ventricular electro grams and arterial blood pressure were displayed simultaneously on an oscilloscope and recorded at a paper speed of 25 to 150 mrnls with an Electronics for Medicine VR-16 recorder. Programmed ventricular stimu• lation was performed with a programmable stimulator (Bloom Associates, Ltd.) using stimuli with a current intensity of twice diastolic threshold and a duration of 2 ms. In every patient. the diastolic excitability threshold was 0.7 rnA or less.
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INTRA VENOUS VERSUS ORAL AMIODARONE Programmed ventricular stimulation was performed ini• tially at the right ventricular apex with single and double extrastimuli at two basic drive cycle lengths (usually 600 and 400 ms). If sustained ventricular tachycardia was not induced, stimulation was repeated at the right ventricular septum or outflow tract. This was followed by programmed ventricular stimulation with triple extrastimuli at the right ventricular apex and then at the second right ventricular site.
Ventricular tachycardia was defined as sustained if it had a duration of at least 30 seconds or required direct current countershock for termination. It was defined as nonsustained if it had a duration of six beats to 30 seconds. In each patient, sustained ventricular tachycardia was induced at least once in the control state. In five patients direct current counter• shock was needed to terminate the tachycardia artd therefore this arrhythmia was induced only once before the admin• istration of amiodarone. In three patients direct current coun• tershock was not needed and ventricular tachycardia was induced at least twice in the baseline state.
The duration of the QRS complex during ventricular pac• ing was used as an index of intraventricular conduction. Incremental pacing was performed at the right ventricular apex at cycle lengths of 600, 500. 400, 350, 300, 275 and 250 ms for 15 to 20 complexes. The last several complexes of each pacing train were recorded at a paper speed of 1 ~O mrnls. The effective refractory period at the right ventricular apex was then determined at a basic drive cycle length of 500 ms, immediately before the administration of amiodarone.
Testing of intravenous amiodarone. Amiodarone was administered intravenously in a dose of 10 mg/kg, at a rate of 50 mg/min. This resulted in a 10 to 20 mm Hg decrease in systolic blood pressure, but no patient developed symp• tomatic hypotension. The electrode catheter positioned at the right ventricular apex was not moved during the period of drug infusion. Five minutes after completion of the amio• darone infusion, determination of the effective refractory period at the right ventricular apex was repeated, followed by incremental ventricular pacing. The electrocardiographic standardization was the same as that used in the initial study. Programmed ventricular stimulation was then performed us• ing a protocol identical to that used before drug adminis• tration. The end point of the stimulation protocol was the induction of sustained ventricular tachycardia. A blood sam• ple for determination of the serum levels of amiodarone and desethylamiodarone was drawn when the stimulation pro• tocol was completed (15 to 20 minutes after completion of the admiodarone infusion).
Testing of oral amiodarone. Oral amiodarone therapy was initiated at a dose of 1,200 mg/day for 5 days, followed by 800 mg/day for 1 month and then 600 mg/day for 1 month. No patient was treated with any other antiarrhythmic drug. After a mean of 8.9 ± 1 weeks (range 8 to 10) of treatment with amiodarone (mean cumulative dose 46.1 ± 1.3 g). an electrophysiologic study was repeated. An elec- *Desethylamiodarone was not detected in any patient aiter intravenous amiodarone administration. tNormal range 80 to 350 pg/ml. T3 = triiodothyronine. trode catheter was positioned in the right ventricular apex such that the QRS complexes during ventricular pacing were similar in configuration to the paced QRS complexes in the baseline study. The right ventricular effective refractory period was determined at a basic drive cycle length of 500 ms and incremental right ventricular pacing was performed as in the baseline study to assess the rate-dependent effects of oral amiodarone on intraventricular conduction. Pro• grammed ventricular stimulation was then performed using the same protocol as before. The end point of the stimulation protocol was one induction of ventricular tachycardia re• quiring direct current countershock or two or more induc• tions of sustained ventricular tachycardia that could be ter• minated by overdrive pacing. Programmed stimulation was performed at the same two right ventricular sites as in the baseline study. On completion of the electrophysiologic study, blood samples were drawn for determination of serum levels of amiodarone, desethylamiodarone and reverse T3 (24 to 28 hours after the last oral dose of amiodarone).
Data analysis. The electrocardiographic lead with the most clearly defined onset and offset of the paced QRS complex was used to measure the QRS duration during ventricular pacing. The same lead Was used for all mea• surements in each patient. Patients in whom the onset or offset of the QRS complex was not well defined in any of the three monitored leads were not included in this study. The duration of the last QRS complex of each pacing train was measured independently in blinded fashion by two ob• servers. Intra-and interobserver variability was less than 5%.
All statistical comparisons were performed with a paired t test. Values are expressed as mean ± 1 SO.
Results
Serum levels of amiodarone, desethylamiodarone and reverse T 3 ( Table 1) . The mean serum level of amiodarone after intravenous amiodarone administration was 3.8 ± 0.7 JLg/ml; desethylamiodarone was not detected in any patient. After 2 months of treatment with oral amiodarone, the mean serum levels of amiodarone and desethylamiodarone were 2.0 ± 0.7 and 1.5 ± 0.8 JLg/ml, respectively. The baseline mean reverse T 3 level was 284 ± 32 pg/ml (normal range C  IV  Oral  C  IV  Oral  C  IV  Oral   220  230  310  168  181  234  168  207  286  250  250  350  2  210  240  270  160  164  184  160  208  226  250  250  300  3  240  260  320  200  227  260  260  255  294  275  275  350  4  200  210  270  127  127  166  127  160  194  250  250  300  5  280  290  340  140  147  174  140  160  194  300  350  400  6  260  270  300  114  114  134  114  140  143  250  275   400   7  190  220  270  180  183  186  180  220  214  250  250  275   8   240  260  290  173  193  190  173  227  203  250  275  350 *QRS duration at a ventricular paced cycle length (PCL) of 600 ms; tQRS duration at the minimal (Min) paced cycle length resulting in complete ventricular capture; *minimal paced cycle length resulting in complete ventricular capture. C = control; IV = intravenous; PCL = paced cycle length; RVERP = right ventricular effective refractory period.
Control

Intravenous Amiodarone
Oral Amiodarone Figure 1 . Patient 1. The rate-dependent effects of intravenous and chronic oral amiodarone therapy on QRS duration. Shown are the last two to three QRS complexes of a train of 15 to 20 paced complexes. In the control state, the QRS duration was 168 ms at a paced cycle length of both 600 and 250 ms. After intravenous amiodarone, QRS duration increased by 8% to 181 ms at a paced cycle length of 600 ms and by 23% to 207 ms at a paced cycle length of 250 ms. The rate-dependent prolongation in QRS duration was markedly accentuated after 2 months of treatment with oral amiodarone. At a paced cycle length of 600 ms, QRS duration increased by 39% over control (to 234 ms) and increased by 70% to 286 ms at a paced cycle length of 350 ms. At paced cycle lengths shorter than 350 ms, there was 2: 1 ventricular capture. 80 to 350). After 2 months of treatment with oral amio• darone, the mean reverse T J level was 667 ± 397 pg/ml. Effects on right ventricular effective refractory period ( Table 2 ). The baseline mean right ventricular effective refractory period was 230 ± 30 ms. This value increased in each patient by 10 to 30 ms to a mean of 248 ± 27 ms (p < 0.001) after intravenous amiodarone therapy and in• creased by 40 to 90 ms over baseline to a mean of 296 ± 26 ms (p < 0.00 1) after chronic oral therapy. The mean ventricular effective refractory period after oral amiodarone was significantly greater than after intravenous amiodarone (p < 0.001).
Effects on intraventricular conduction ( Table 2 ). In the baseline state, QRS duration was the same at all ven• tricular paced cycle lengths, and the shortest paced cycle length associated with complete ventricular capture was 260 ± 19 ms. After intravenous and oral amiodarone therapy, the shortest paced cycle length associated with complete ventricular capture was 272 ± 34 ms (p > 0.05 versus control) and 341 ± 46 ms (p < 0.001 versus control and intravenous admiodarone), respectively.
After intravenous amiodarone, there was a rate-depen• dent increase in QRS duration (Fig. I) . At a ventricular paced cycle length of 600 ms, QRS duration was unchanged compared with the control value (p > 0.05), whereas at a paced cycle length of 250 ms, QRS duration increased by 25 ± 3% (p < 0.001) (Fig. 2) .
After oral amiodarone therapy at a ventricular paced cycle length of 600 ms, there was also a rate-dependent increase in QRS duration (Fig. 1 ). The QRS duration in• creased by 21 ± 12% over the control value (p < 0.01) at a ventricular paced cycle length of 600 ms and increased by 42 ± 20% (p < 0.05) at a paced cycle of 350 ms (Fig.   2 ). At the shortest cycle length associated with complete ventricular capture, the QRS duration after oral amiodarone was increased by 39 ± 18% over the pre-drug value (p < 0.01 ). The increment over control in QRS duration at the shortest paced cycle length associated with complete ven• tricular capture was not significantly greater after oral amio• darone (39 ± 18%) than after intravenous amiodarone (24 ± 5%, P > 0.05). At paced cycle lengths of 600,500 and 400 ms, the magnitude of change in the QRS duration com• pared with control was greater after oral than after intra• venous amiodarone (p < 0.05) (Fig. 2) . Examining the relative effects of intravenous and oral amiodarone on QRS duration, the effect of oral amiodarone was more pro• nounced in six patients (Cases 1 to 6) and not more pro• nounced in two patients (Cases 7 and 8, Fig. 3 ).
Effects on ventricular tachycardia induction. The configuration and cycle length of ventricular tachycardia induced in the control study are described in Table 3 . After intravenous amiodarone, ventricular tachycardia became nonsustained in one patient and noninducible in two patients (Fig. 4) . In these two patients (Cases I and 6), the coupling 0 intervals that resulted in the induction of tachycardia in the control state no longer resulted in ventricular capture after intravenous amiodarone. Among the other five patients with inducible sustained ventricular tachycardia, the arrhythmia was of the same configuration as in the control study in three patients and of a different configuration in two. In the six patients who had inducible ventricular tachycardia after intravenous amiodarone, the ventricular tachycardia cycle length was unchanged in one, shortened in one and length• ened in four patients ( Table 3) .
The effects of oral amiodarone on ventricular tachycar• dia induction were different from the effects of intravenous amiodarone. The three patients who had either non inducible or nonsustained ventricular tachycardia after intravenous amiodarone all had inducible sustained ventricular tachy• cardia after oral amiodarone, as did three others (Table 3 ). In Patients 1 and 6, coupling intervals that resulted in ven• tricular capture without ventricular tachycardia induction after intravenous amiodarone did result in tachycardia in• duction after oral amiodarone (Fig. 4) . Two patients had inducible nonsustained ventricular tachycardia (Fig. 5 ). In only four patients was the configuration of the induced ven• tricular tachycardia after oral amiodarone the same as in the control study. In these patients, the coupling intervals of the extrastimuli that induced ventricular tachycardia were consistently 40 to 110 ms longer than the coupling intervals of the extrastimuli that induced tachycardia in the control state (Fig. 4) . In every patient, the ventricular tachycardia cycle length was longer after oral amiodarone than in the control study (mean 336 ± 104 versus 240 ± 90 ms p < Relations among amiodarone, desethylamiodarone and reverse T 3 serum levels and electrophysiologic effects. In six patients (Cases 1 to 6), the QRS duration at comparable paced cycle lengths was greater after oral than after intra• venous amiodarone. In each of these six patients, there was a large increase in the serum reverse T 3 to levels of 515 to 1,545 pg/ml (Fig. 6 ). In contrast, in two patients (Cases 7 and 8) the QRS duration at comparable paced cycle lengths was not greater after oral than after intravenous amiodarone, and in both of these patients the serum reverse T3 level, although increased from baseline, was still within normal limits (Fig. 6 ). There were no other discernible relations among the serum levels of amiodarone, desethylamiodarone or reverse T 3 and the electrophysiologic effects of intra• venous or oral amiodarone.
Discussion
Relative effects of intravenous and oral amioda• rone. Our results demonstrate that both intravenous and oral amiodarone prolong the ventricular effective refractory period and slow intraventricular conduction in a rate-de• pendent fashion, but usually to different degrees. After 2 months of oral amiodarone therapy, the ventricular effective refractory period is consistently prolonged by 30 to 80 ms beyond the 10 to 30 ms increase that occurs acutely after intravenous amiodarone. In contrast, the rate-dependent slowing of intraventricular conduction that occurs acutely after intravenous amiodarone is not consistently accentuated after oral amiodarone. The variable response of ventricular refractoriness and intraventricular conduction to intravenous and oral amiodarone suggests that different mechanisms may underlie the relative effects of intravenous and oral amiodarone on refractoriness and conduction.
EtTects on ventricular refractoriness. A prior study (23) suggested that amiodarone's electrophysiologic effects on the myocardium may be mediated by a disturbance in thyroid hormone metabolism. Prolongation of the QT in• terval and suppression of ventricular premature depolari• zations during treatment with oral amiodarone were found to correlate with elevation in the serum level of reverse T 3. An increase in the serum level of reverse T 3 during therapy 
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>--1_-\· Figure 4 . Patient 6. Results of programmed ventricular stimula• tion after intravenous and chronic oral amiodarone therapy. Three electrocardiographic leads (V I, I and III) are shown. In the control state, sustained ventricular tachycardia, cycle length (CL) 200 ms, which had a left bundle branch block configuration and a superior axis, was induced by triple extrastimuli at the right ventricular outflow tract. Shown are the SISI/SIS2/S2S3/S3S4 coupling intervals that induced the ventricular tachycardia. After intravenous amio• darone there was not complete ventricular capture at the same coupling intervals that had induced ventricular tachycardia in the control study, and ventricular tachycardia was not inducible. Shown are the shortest SISI/SIS2/S2S3/S3S4 coupling intervals that resulted in complete ventricular capture at the right ventricular outflow tract. Two repetitive complexes were induced, but not ventricular tachycardia. After 2 months of treatment with oral amiodarone, sustained ventricular tachycardia, cycle length 290 ms, again with a left bundle branch block configuration and a superior axis, was induced by triple extrastimuli at the right ventricular outflow tract. Note that the coupling intervals of the extrastimuli that induced ventricular tachycardia are considerably longer than in the control study.
with amiodarone reflects a block in the peripheral conversion of tetraiodothyronine (T4) to T 3 , and increased monode• iodination of T 4 to reverse T 3 (24) . However, in our study, the serum level of reverse T 3 was not always elevated above the normal range after 2 months of treatment with oral amiodarone. Therefore, the larger increase in the ventricular effective refractory period that occurs after 2 months of oral treatment with amiodarone compared with that after intra• venous treatment is unlikely to be attributable to a distur• bance in thyroid hormone metabolism. Amiodarone has been demonstrated to acutely prolong action potential duration in a guinea pig papillary muscle preparation (25) . The observation that intravenous amio• darone significantly prolongs ventricular refractoriness sug• gests that amiodarone also has a direct effect on action potential duration in ventricular myocardium in humans. Potentiation of this effect by oral amiodarone cannot be explained by differences in the serum level of amiodarone, because the amiodarone serum level was consistently higher during testing of intravenous amiodarone than during testing of oral amiodarone. Possible explanations for the greater increase in ventricular effective refractory period after oral compared with intravenous therapy include 1) a higher tissue level of amiodarone after long-term administration; 2) ac• cumulation during chronic oral therapy of desethylamio• darone, which is not detectable acutely after administration of intravenous amiodarone and which may have a direct Whereas prior studies (18, 19) have demonstrated that intravenous amiodarone acutely prolongs refractoriness in the atrioventricular node and in accessory atrioventricular connections, an acute effect on ventricular refractoriness has not been previously demonstrated (15, 18, 19) . However, prior studies utilized a dose of intravenous amiodarone of 5 mg/kg, whereas a dose of 10 mg/kg was used in our study.
Effects on intraventricular conduction. In an isolated papillary muscle preparation, amiodarone was found (25) to block sodium channels in a rate-dependent fashion and to thereby decrease the maximal rate of rise of the action potential upstroke. Because intraventricular conduttion de• perlds predominantly on the fast sodium current, prolon• gation of intraventricular conduction would also be expected to occur in a rate-dependent fashion. A rate-dependent pro• longation of intraventricular conduction, as reflected by changes in Q}{S duration during ventricular pacing, was demonstrated in response to intravenous amiodarone in a prior study (20) and confirmed in the present study. This rate-dependent slowing of intraventricular conduction was markedly accentuated after long-term treatment with oral amiodarone in some patients, but not in others. Augmen-tation of the effects of amiodarone on intraventricular con• duction after long-term therapy correlated not with the serum levels of amiodarone or desethylamiodarone, but with an elevation in the serum level of reverse T 3. In each patient whose reverse T3 serum level was elevated beyond the nor• mal range after 2 months of treatment with amiodarone, slowing of intraventricular conduction was more pro• nounced by oral than by intravenous amiodarone. In con• trast, in both patients who had a normal serum level of reverse T 3 after 2 months of amiodarone therapy, the effects of oral amiodarone on intraventricular conduction were sim• ilar to the effects of intravenous amiodarone. This suggests that the direct effects of amiodarone on intraventricular con• duction may be potentiated indirectly by its effects on thy• roid hormone metabolism.
By blocking the peripheral conversion of T4 to T 3 , or by competing with T3 binding to nuclear receptor sites, or both, amiodarone (or desethylamiodarone) may induce a state of hypothyroidism (24, 26) . The principal electrophysiologic effect of hypothyroidism on the action potential is to prolong its duration (24) . Prolongation of the action potential du• ration (as might occur secondary to an amiodarone-induced disturbance in thyroid hortnone metabolism) would be ex• pected to prolong the period during which sodium channels are inactivated. Mason et al. (25) demonstrated that amio• darone blocks sodium channels that are in the inactivated state. To the extent that an increase in the serum level of reverse T 3 reflects a state of hypothyroidism induced by amiodarone, our results are consistent with potentiation of amiodarone's blockade of sodium channels by a chronic increase in action potential duration. Alternatively, the ap• parent correlation between an elevated reverse T 3 serum level and potentiation of an acute rate-dependent slowing of intraventricular conduction by oral amiodarone may sim• ply reflect two independent end-organ effects that become more pronounced during long-term amiodarone therapy in some patients but not in others.
Effects on ventricular tachycardia induction. In the present study, intravenous amiodarone was found to be ca• pable of either suppressing or modifying the induction of ventricular tachycardia by programmed stimulation. These results confirm the findings of Hariman et al. (15) , who reported that intravenoUs amiodarone suppressed the induc• tion of ventricular tachycardia in three of seven patients and converted sustained to nonsustained ventricular tachycardia in an additional two patients. The reason that amiodarone suppresses or modifies the induction of ventricular tachy• cardia in some patients but not in others is not clear; there was no discernible relation between the absolute or relative effects of amiodarone on the right ventricular effective re• fractory period or intraventricular conduction and its effects on the induction of ventricular tachycardia. However, any such conclusions are limited by the inability to determine amiodarone's effects on the actual substrate of the reentrant circuit. Our present observations relate to refractoriness measured at the right ventricular apex and global intraven• tricular conduction. The effects of amiodarone on conduc• tion and refractoriness within the reentrant circuit respon• sible for ventricular tachycardia could not be determined and may differ from its global effects.
The effects of oral amiodarone on the induction of ven• tricular tachycardia were discordant with the acute effects of intravenous amiodarone. In two patients in whom intra• venous amiodarone completely suppressed the induction of ventricular tachycardia, sustained ventricular tachycardia was inducible after 2 months of oral treatment. Furthermore, in two patients who had inducible sustained ventricular tachy• cardia after intravenous amiodarone, only nonsustained ven• tricular tachycardia could be induced after oral treatment. These discordant responses to programmed stimulation are presumably due to a difference in the relative effects of intravenous and oral amiodarone on conduction and refrac• toriness within the reentrant circuit responsible for ventric• ular tachycardia. For example, induction of ventricular tachycardia after oral amiodarone by extrastimuli with cou• pling intervals that did not result in induction of ventricular tachycardia after intravenous amiodarone may be attribut• able to a greater degree of slowing of intraventricular con• duction by oral amiodarone. Again, because the effects of amiodarone on the specific substrate for reentry were not determined, this explanation is speculative.
Limitations. 1) Although the duration of the QRS com• plex during ventricular pacing was used as an index of global intraventricular conductioh, this is not a direct measure of intraventricular conduction. 2) The diluent in the intrave• nous form of amiodarone was Tween 80. The electrophysio• logic effects of this diluent were not studied; therefore, its contribution to the changes observed after the administration of intravenous amiodarone is unknown.
Conclusions.
The acute and chronic effects of amio• darone on ventricular refractoriness and conduction are dif• ferent, perhaps because of a variable interplay between the direct and indirect effects of this agent on the myocardial action potential. Long-term amiodarone therapy results in a marked prolongation of ventricular refractoriness beyond the relatively small but significant increase that occurs acutely in response to intravenous amiodarone administration. This may reflect a direct effect of amiodarone that is accentuated by either higher tissue levels of amiodarone or accumulation of desethylamiodarone. Augmentation by oral amiodarone of the acute rate-dependent slowing of intraventricular con• duction that occurs after intravenous administration appears to correlate with an increase in the serum level of reverse T 3 , suggesting that effects on thyroid metabolism may po• tentiate sodium channel blockade by amiodarone. Both in• travenous and chronic oral amiodarone can suppress or mod• ify ventricular tachycardia induced by programmed stimulation, but in a discordant fashion, probably because
